
Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.

September 15, 2021
There is recognized heterogeneity within any given tumor‐type from patient to patient (inter‐patient heterogeneity),..
Read article

July 2, 2021
Use of Rolling-enrollment Designs to Accelerate Clinical Trials
Popular statistical designs, such as CRM (O’Quigley et al., 1990), mTPI-2 (Guo et al., 2017), and i3+3 (Liu et al.,..
Read article

June 9, 2021
Selecting a Clinical Trial Design: How Broadly Should You Explore?
When selecting clinical trial designs, how many design options should a sponsor explore? Would a sponsor feel more..
Read article

June 2, 2021
A Data-Infused Approach to De-Risking Clinical Trials
For many decades the Pareto Frontier has been employed by actors in the private sector to evaluate and understand the..
Read article

May 28, 2021
Use of Bayesian Approach in Basket Trial Design
Advancements in biomarkers and momentum in precision medicine has paved the foundation for complex studies like basket..
Read article

May 14, 2021
Starting the Conversation Early: Incorporating Business Considerations in Optimal Selection of Trial Design
When developing clinical strategy, applying familiar business principles to the specific requirements of clinical..
Read article

May 4, 2021
New Publication on Adaptive Platform Trials
As healthcare systems across the world, continue to grapple with the pressures of COVID-19, Cytel advances yet another..
Read article

April 28, 2021
Trial Selection: From Art to Science
Recently, Cytel co-founder Professor Cyrus Mehta noted that, “Clinical trial design selection is too much like an art,..
Read article

April 20, 2021
New Dimensions of Clinical Trial Optimization
For much of the past three decades, even as methodologies for clinical trial design have advanced and refined, the idea..
Read article